The global market for botanical and plant-derived drugs is expected to grow from $38.7 billion in 2025 and is projected to reach $58.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2025 to 2030.
The use of conventional treatments based on regional herbs, combined with technological advancements, has gained popularity in recent decades for treating wounds and illnesses. New bioactive compounds derived from plants have been developed as a result, although post-marketing studies and clinical trials have not been successful enough to meet FDA regulations.
Throughout history, plants have been utilized as a source of medicine, and they still form the basis of many modern medications. But even though botanical medicine served as the foundation for the modern pharmaceutical industry, synthetic techniques in drug development are now commonplace.
The pharmaceutical and biotech industries have accepted the new reality brought about by science-driven translational research and botanical development, resulting in significant shifts in approaches, technology, and disciplines.
This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.
This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.
The use of conventional treatments based on regional herbs, combined with technological advancements, has gained popularity in recent decades for treating wounds and illnesses. New bioactive compounds derived from plants have been developed as a result, although post-marketing studies and clinical trials have not been successful enough to meet FDA regulations.
Throughout history, plants have been utilized as a source of medicine, and they still form the basis of many modern medications. But even though botanical medicine served as the foundation for the modern pharmaceutical industry, synthetic techniques in drug development are now commonplace.
The pharmaceutical and biotech industries have accepted the new reality brought about by science-driven translational research and botanical development, resulting in significant shifts in approaches, technology, and disciplines.
Report Scope
The report provides an overview of the global market for botanical and plant-derived drugs and analyzes market trends. It includes global revenue ($ million) for 2024 as the base year data and estimated data for the forecast period, which is 2025 through 2030. The market is segmented based on product, application and region. By type, the market is segmented into plant-derived drugs and botanicals.This report primarily focuses on drugs, rather than supplements or dietary substitutes. By application, the market is segmented into cancer, cardiovascular diseases, central nervous system disorders, infectious diseases and other. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with additional focus on major countries in these regions. North America includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe. The Asia-Pacific region includes China, Japan, India, South Korea, and the Rest of Asia-Pacific. Rest of the world includes South America and Middle East and Africa.
This report focuses on the significant driving trends and challenges that affect the market. It analyzes environmental, social, and corporate governance (ESG) developments. The report includes an analysis of the competitive landscape, with a focus on the key firms in the global market. It also has a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments.
The report includes:
- 47 data tables and 47 additional tables
- An overview of the global market for botanical and plant-derived drugs
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
- Evaluation of the current market size and revenue growth prospects specific to the botanical and plant-derived drugs, accompanied by a market share analysis by type, application and region
- Analysis of current and future demand in the botanical and plant-derived drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
- Detailed information on some of the botanical or plant products that have received FDA approval for prescription medications, such as Veregen and Fulyzaq, and a discussion of their therapeutic advantages over synthetic substitutes
- Analysis of drivers, challenges and opportunities affecting market growth
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
- Profiles of major companies within the industry, including Bayer, Novartis, Jaguar Health Inc., Jazz Pharmaceuticals, and Bristol Myers Squibb Co.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologiesand Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in the Botanical and Plant-Derived Drugs Market: An ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- ANI Pharmaceuticals Inc.
- Bayer AG
- Bristol-Myers Squibb Co.
- Chiesi Farmaceutici S.p.A.
- Fresenius Kabi AG
- GSK plc
- Jaguar Health
- Jazz Pharmaceuticals Inc.
- Johnson & Johnson
- Mallinckrodt
- MediWound
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | December 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 38.7 Billion |
| Forecasted Market Value ( USD | $ 58.1 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
